Serotonin SyndromeMoclobemideSerotoninClinical Trials, Phase IV as TopicSerotonin AgentsMuscle HypertoniaMyoclonusChlorpheniramineSerotonin Uptake InhibitorsMonoamine Oxidase InhibitorsDrug OverdosePsychomotor AgitationReflex, AbnormalAntitussive AgentsDextromethorphanAcetamidesSweatingOxazolidinonesSerotonin Plasma Membrane Transport ProteinsProduct Surveillance, PostmarketingReceptors, SerotoninTremorReceptor, Serotonin, 5-HT2AToxicity TestsReceptor, Serotonin, 5-HT1ASerotonin AntagonistsChemical PrecipitationReceptor, Serotonin, 5-HT2CDiagnostic Tests, RoutineReceptor, Serotonin, 5-HT2BReceptors, Serotonin, 5-HT2Receptor, Serotonin, 5-HT1BSerotonin Receptor AgonistsToxicity Tests, AcuteReceptors, Serotonin, 5-HT1Serotonin 5-HT2 Receptor AntagonistsReceptors, Serotonin, 5-HT3Serotonin 5-HT2 Receptor AgonistsDose-Response Relationship, DrugTryptophan HydroxylaseSerotonin 5-HT1 Receptor AgonistsReceptors, Serotonin, 5-HT4Serotonin 5-HT1 Receptor AntagonistsLethal Dose 50Hydroxyindoleacetic AcidDrug Administration ScheduleAntineoplastic Combined Chemotherapy ProtocolsToxicity Tests, ChronicFluoxetineTime FactorsAntineoplastic AgentsTreatment OutcomeCitalopramSerotonergic NeuronsKetanserin5-HydroxytryptophanRaphe NucleiRats, Sprague-DawleyPrecipitinsParoxetine8-Hydroxy-2-(di-n-propylamino)tetralinMethysergideFenclonineCell SurvivalBrainCisplatinInfusions, IntravenousLiverCalcium PhosphatesReceptor, Serotonin, 5-HT1DAntigen-Antibody ComplexRabbits5,7-DihydroxytryptamineNo-Observed-Adverse-Effect LevelFluorouracilAdministration, OralDrug InteractionsMaximum Tolerated DoseNeoplasmsImmunodiffusionAntibodies, MonoclonalCells, CulturedBiogenic MonoaminesNeuronsCell LineCombined Modality TherapyHydrogen-Ion ConcentrationSerotonin 5-HT3 Receptor AntagonistsDoxorubicinSolubilityKineticsImmune SeraDopamineToxicologyImmunoelectrophoresisRats, WistarMolecular WeightAntidepressive AgentsBehavior, AnimalDisease Models, Animal